Glaukos Co. (NYSE:GKOS – Get Free Report) Director Marc Stapley sold 6,250 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now owns 34,076 shares of the company’s stock, valued at $4,291,190.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Glaukos Price Performance
GKOS stock opened at $130.00 on Thursday. The company has a market capitalization of $6.55 billion, a P/E ratio of -45.14 and a beta of 1.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.68 and a current ratio of 5.48. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $130.13. The business has a 50-day simple moving average of $119.36 and a two-hundred day simple moving average of $105.79.
Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) EPS. Research analysts expect that Glaukos Co. will post -2.25 EPS for the current fiscal year.
Hedge Funds Weigh In On Glaukos
Analyst Upgrades and Downgrades
GKOS has been the subject of a number of recent analyst reports. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Truist Financial restated a “buy” rating and issued a $145.00 target price (up from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Stifel Nicolaus raised their target price on Glaukos from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th. Finally, Morgan Stanley raised their target price on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $127.73.
Check Out Our Latest Stock Analysis on Glaukos
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Stories
- Five stocks we like better than Glaukos
- The 3 Best Retail Stocks to Shop for in August
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- What Does Downgrade Mean in Investing?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.